Different studies reported that patients with BOS have diminished levels of Tregs, a subset of CD4+ T cells, and that the misbalance between Tregs and Th17 (a CD4+ T-cell subset producing interleukin-17) may predict a risk of developing BOS [6]. The gene discussed is IL17A; the disease is Buschke-Ollendorff syndrome.